194 related articles for article (PubMed ID: 27760426)
21. Targeted Downregulation of
Park SY; Seo J; Chun YS
J Korean Med Sci; 2019 Aug; 34(33):e225. PubMed ID: 31436053
[TBL] [Abstract][Full Text] [Related]
22. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
[TBL] [Abstract][Full Text] [Related]
23. Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.
Aillaud I; Funke SA
Cell Mol Neurobiol; 2023 Apr; 43(3):951-961. PubMed ID: 35596819
[TBL] [Abstract][Full Text] [Related]
24. Integrating in vitro and in silico approaches to evaluate the "dual functionality" of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils.
Haj E; Losev Y; Guru KrishnaKumar V; Pichinuk E; Engel H; Raveh A; Gazit E; Segal D
Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1565-1575. PubMed ID: 29634991
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tau amyloid formation and disruption of its preformed fibrils by Naphthoquinone-Dopamine hybrid.
Paul A; Viswanathan GK; Huber A; Arad E; Engel H; Jelinek R; Gazit E; Segal D
FEBS J; 2021 Jul; 288(14):4267-4290. PubMed ID: 33523571
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice.
Davidowitz EJ; Krishnamurthy PK; Lopez P; Jimenez H; Adrien L; Davies P; Moe JG
J Alzheimers Dis; 2020; 73(1):147-161. PubMed ID: 31771053
[TBL] [Abstract][Full Text] [Related]
27. Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
Rickard JE; Horsley D; Wischik CM; Harrington CR
Methods Mol Biol; 2017; 1523():129-140. PubMed ID: 27975248
[TBL] [Abstract][Full Text] [Related]
28. Development of tau aggregation inhibitors for Alzheimer's disease.
Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
[TBL] [Abstract][Full Text] [Related]
29. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
Jouanne M; Rault S; Voisin-Chiret AS
Eur J Med Chem; 2017 Oct; 139():153-167. PubMed ID: 28800454
[TBL] [Abstract][Full Text] [Related]
30. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F; Grueninger F; Tolnay M
Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
[TBL] [Abstract][Full Text] [Related]
31. Genetic reduction of tyramine β hydroxylase suppresses Tau toxicity in a Drosophila model of tauopathy.
Nangia V; O'Connell J; Chopra K; Qing Y; Reppert C; Chai CM; Bhasiin K; Colodner KJ
Neurosci Lett; 2021 Jun; 755():135937. PubMed ID: 33910059
[TBL] [Abstract][Full Text] [Related]
32. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.
Malhis M; Kaniyappan S; Aillaud I; Chandupatla RR; Ramirez LM; Zweckstetter M; Horn AHC; Mandelkow E; Sticht H; Funke SA
Chembiochem; 2021 Nov; 22(21):3049-3059. PubMed ID: 34375027
[TBL] [Abstract][Full Text] [Related]
33. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
34. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
Zilka N; Korenova M; Novak M
Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
[TBL] [Abstract][Full Text] [Related]
35. Tryptophan-tyrosine dipeptide improves tau-related symptoms in tauopathy mice.
Ano Y; Takaichi Y; Ohya R; Uchida K; Nakayama H; Takashima A
Nutr Neurosci; 2023 Aug; 26(8):766-777. PubMed ID: 35816407
[TBL] [Abstract][Full Text] [Related]
36. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
37. Tau protein aggregation: Key features to improve drug discovery screening.
Giovannini J; Smeralda W; Jouanne M; Sopkova-de Oliveira Santos J; Catto M; Voisin-Chiret AS
Drug Discov Today; 2022 May; 27(5):1284-1297. PubMed ID: 35085785
[TBL] [Abstract][Full Text] [Related]
38. Pore-former enabled seeding of tau in rats: Alleviation by memantine and lithium chloride.
Mietelska-Porowska A; Gasiorowska A; Palasz E; Koss DJ; Riedel G; Niewiadomska G
J Neurosci Methods; 2019 May; 319():47-59. PubMed ID: 30448465
[TBL] [Abstract][Full Text] [Related]
39. Effects of Deferasirox in Alzheimer's Disease and Tauopathy Animal Models.
Kwan P; Ho A; Baum L
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327557
[TBL] [Abstract][Full Text] [Related]
40. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
Das G; Ghosh S
ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
